News

Merck to pay $58m in settlement over rofecoxib advertising

BMJ 2008; 336 doi: 10.1136/bmj.39591.705231.DB (Published 29 May 2008)
Cite this as: BMJ 2008;336:1208.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fred Charatan
  1. 1Florida

    Merck & Company has agreed to pay $58m (£29m; €37m) to settle allegations that advertising for its analgesic rofecoxib (Vioxx) played down potential health risks.

    The civil settlement ends investigations by 29 US states and the District of Columbia into Merck’s previous advertising practices for the drug. Tom Corbett, attorney general of Pennsylvania, said that the agreement is the largest in a multi-state consumer protection case involving drugs.

    Mr Corbett said that in 1999 Merck had launched “an aggressive and deceptive advertising …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular